Dr. Loeb on Tests for the Management of Prostate Cancer

Stacy Loeb, MD
Published: Tuesday, Jun 06, 2017



Stacy Loeb, MD, assistant professor of Urology and Population Health at New York University, discusses test options to determine the management of patients newly diagnosed with prostate cancer.

According to Loeb, there are many tests on the market for patients with newly diagnosed prostate cancer. Oncotype DX gives the risk of finding adverse pathology if the patient had a prostatectomy. The Prolaris test gives the risk of dying from prostate cancer in 10 years without any treatment. The Decipher test investigates the patient’s chance of having high-grade disease, metastasis, or prostate cancer death.

All these options are available to patients, explains Loeb. The patient is able to decide which test result will be most beneficial to them.
 
SELECTED
LANGUAGE


Stacy Loeb, MD, assistant professor of Urology and Population Health at New York University, discusses test options to determine the management of patients newly diagnosed with prostate cancer.

According to Loeb, there are many tests on the market for patients with newly diagnosed prostate cancer. Oncotype DX gives the risk of finding adverse pathology if the patient had a prostatectomy. The Prolaris test gives the risk of dying from prostate cancer in 10 years without any treatment. The Decipher test investigates the patient’s chance of having high-grade disease, metastasis, or prostate cancer death.

All these options are available to patients, explains Loeb. The patient is able to decide which test result will be most beneficial to them.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Publication Bottom Border
Border Publication
x